Novavax Reports Q2 2025 Earnings with Revenue Drop and Milestone Payment from Sanofi
Novavax reported Q2 2025 earnings with total revenue of $239 million, a decline from $415 million in the prior-year quarter. The drop was attributed to anticipated milestone and licensing revenue flows. A $175 million milestone payment from Sanofi due to Nuvaxovid FDA approval is expected in Q3.
Topics: cash reserves earnings milestone payment operating expenses revenue